About the Company
Provention Bio, Inc. is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Biologics License Application (BLA) for teplizumab, its lead investigational drug candidate, for the delay or prevention of clinical type 1 diabetes in at-risk individuals, has been filed by the U.S. Food and Drug Administration (FDA). The Company's pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PRVB News
Provention Bio (NASDAQ: PRVB)
Provention Bio is a clinical-stage biopharmaceutical company dedicated to sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune ...
Sanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Information
regarding the acquisition of Provention Bio Inc (NASDAQ: PRVB). Sanofi agreed to acquire Provention Bio at $25 per share in a deal valued at $2.9 billion. The agency, it added, needed more time to ...
Sanofi Agrees to Pay $2.9 Billion For Provention Bio
(Bloomberg) -- Sanofi agreed to buy Provention Bio Inc. in a $2.9 billion deal intended to bolster the French drugmaker’s portfolio of diabetes medicines with a new therapy recently approved in ...
Provention Bio Inc (PRVB)
View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Provention prices type 1 diabetes drug Tzield at $194,000
Provention Bio has priced its new type 1 diabetes (T1D) prevention therapy Tzield at $13,850 per vial – equivalent to almost $194,000 for its 14-day course – a higher level than had been ...
Provention finally gets FDA nod for type 1 diabetes drug teplizumab
At its second attempt, Provention Bio has secured FDA approval for teplizumab, as a treatment to delay late-stage type 1 diabetes (T1D) in at-risk individuals – becoming the first disease ...
PALI Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company ...
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
FREMONT, CA, March 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire-- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ...
Telesis Bio Inc TBIO
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
bluebird bio, Inc. (BLUE)
SOMERVILLE, Mass., March 11, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio") today announced it has signed its first Medicaid outcomes-based agreement for LYFGENIA™ (lovotibeglogene ...
TRML Tourmaline Bio, Inc.
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops TOUR006, a human anti-IL-6 monoclonal ...
Gossamer Bio Inc GOSS
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...